Disease landscape

Myelodysplastic Syndromes (MDS) clinical trials

Get alerts when Myelodysplastic Syndromes (MDS) trials change

561 active trials 329 recruiting 41 Phase 3 259 sponsors 94 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days showing 49 of 94 changes on 20 trials

2026-08-28
Recruitment suspended
Recruitment suspended: Unacceptable Toxicity
NCT03816319 TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or… · National Cancer Institute (NCI) · Phase 1
2026-08-21
Trial terminated
Trial terminated: \<75% participants
Primary completion moved earlier: 2026-11-30 → 2026-08-14
Completion moved earlier: 2026-11-30 → 2026-08-14
NCT02392572 ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk… · M.D. Anderson Cancer Center · Phase 1/2
2026-08-18
Withdrawn before enrolling
Trial withdrawn: FDA requested significant changes to the study protocol
Enrollment reduced: 25 → 0 participants
NCT07387354 Pacritinib With Aza for Upfront Myelodysplastic Syndrome · Thomas Jefferson University · Phase 1/2
2026-08-07
Trial terminated
Trial terminated: The study was closed due to the end of funding.
NCT04994808 Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem… · Fred Hutchinson Cancer Center · Phase 2
2026-08-11
Recruitment suspended
Recruitment suspended: Recruitment on hold with plans to open to accrual again soon.
NCT06492707 DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse… · Fred Hutchinson Cancer Center · Phase 1
2026-09-04
Primary completion pushed: 2026-05-31 → 2026-10-15
Completion pushed: 2026-08-31 → 2026-11
NCT04635384 Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT)… · CareDx
2026-09-03
Primary completion pushed: 2028-12 → 2029-09
Recruitment opened
Trial sites expanded: 4 → 17 locations
Completion pushed: 2028-12 → 2029-09
NCT07025824 Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With… · Technische Universität Dresden · Phase 2
2026-09-02
Primary completion pushed: 2026-06-23 → 2027-05-11
Completion pushed: 2026-06-23 → 2027-05-11
NCT04262843 Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell… · City of Hope Medical Center · Phase 2
2026-08-11
Primary completion pushed: 2025-12 → 2027-12
Primary endpoint(s) modified
Enrollment increased: 40 → 59 participants
Completion pushed: 2026-01 → 2028-01
Trial arms changed: 1 → 3
NCT04608110 A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome · Taiho Pharmaceutical Co., Ltd. · Phase 1
2026-08-28
Primary completion pushed: 2025-06 → 2026-03-31
Completion pushed: 2026-12 → 2027-12
NCT05153226 GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG · DKMS gemeinnützige GmbH · Phase 3
2026-08-20
Primary completion pushed: 2026-08-31 → 2027-08-31
Completion pushed: 2026-08-31 → 2027-08-31
NCT05600894 Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic… · National Cancer Institute (NCI) · Phase 2
2026-08-18
Primary completion pushed: 2026-02-01 → 2026-12-24
Completion pushed: 2026-06-30 → 2026-12-30
NCT06001385 HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced… · Center for International Blood and Marrow Transplant Research · Phase 2
2026-08-08
Primary completion pushed: 2026-08-31 → 2030-08-31
Completion pushed: 2026-08-31 → 2030-08-31
NCT05092451 Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in… · M.D. Anderson Cancer Center · Phase 1/2
2026-08-07
Primary completion pushed: 2026-08-31 → 2028-08-31
Completion pushed: 2026-08-31 → 2028-08-31
NCT02861417 Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating… · M.D. Anderson Cancer Center · Phase 2
2026-08-15
Primary completion pushed: 2026-06-30 → 2027-05-25
Completion pushed: 2026-06-30 → 2027-05-25
NCT04537871 Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study · City of Hope Medical Center
2026-08-15
Primary completion pushed: 2025-10-30 → 2026-10-30
Completion pushed: 2026-05-01 → 2026-12-01
NCT05150561 Muscle Dysfunction in Patients With Haematological Diseases · Rigshospitalet, Denmark
2026-08-13
Primary completion pushed: 2026-06-22 → 2027-09-30
Completion pushed: 2026-11 → 2027-11
NCT03680677 Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With… · Abramson Cancer Center at Penn Medicine
2026-08-13
Primary completion pushed: 2026-10-01 → 2028-07-01
Completion pushed: 2026-10-01 → 2028-07-01
NCT05444348 Compassionate Communication and Advance Care Planning to Improve End of Life Care in… · Christoffer Johansen
2026-08-12
Primary endpoint(s) modified
Trial arms changed: 1 → 2
NCT06529731 Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid… · Sawa Ito, MD · Phase 2
2026-08-27
Enrollment reduced: 44 → 30 participants
Trial completed
Completion moved earlier: 2027-02 → 2026-06
NCT02494167 Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) · Baylor College of Medicine · Phase 1

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-21 NCT07780552 CHIP in Health and Disease VASCage GmbH new
2026-08-21 NCT07779031 A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine… Liping Dou new Phase 1/2
2026-08-13 NCT07763054 Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia… Haikou Affiliated Hospital of Central South University Xiangya School of Medicine new
2026-08-12 NCT07761533 PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS Chaser Therapeutics, Inc. new Phase 1/2
2026-08-07 NCT07753148 Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of… Regeneron new Phase 1
2026-08-06 NCT07749976 GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL… Vitruviae new Phase 1/2
2026-07-23 NCT07723703 Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and… Amphista Therapeutics Ltd new Phase 1
2026-07-23 NCT07722988 A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating… Kyntra Bio new Phase 3
2026-07-22 NCT07719348 A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid… Servier new Phase 1/2
2026-07-21 NCT07717164 PRAISE-IR Versus CIBMTR Controls Miltenyi Biomedicine GmbH new

Active trials by phase

Early Phase 1
5
Phase 1
131
Phase 1/2
78
Phase 2
185
Phase 2/3
10
Phase 3
31
Not charted: 121 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 561

NCT IDTitleSponsorStatusUpdated
Phase 3
NCT06465953 Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With… Institut de Recherches Internationales Servier Recruiting 2026-09-03
NCT06499285 A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk… Takeda Recruiting 2026-08-21
NCT07422480 A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low… Takeda Recruiting 2026-07-22
NCT07702578 A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic… TScan Therapeutics, Inc. Recruiting 2026-07-22
NCT04064060 A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other… Celgene Recruiting 2026-07-01
NCT07396480 Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan… First Affiliated Hospital of Zhejiang University Recruiting 2026-03-17
NCT06641414 Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With… Ascentage Pharma Group Inc. Recruiting 2025-11-20
NCT04184505 Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT) Gruppo Italiano Malattie EMatologiche dell'Adulto Recruiting 2025-04-29
NCT05991908 Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating… Shanghai Jiao Tong University School of Medicine Recruiting 2025-02-18
NCT00843882 Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic… National Cancer Institute (NCI) Active, Not Recruiting 2026-09-02
NCT05153226 GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG DKMS gemeinnützige GmbH Active, Not Recruiting 2026-08-27
NCT02521493 Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or… Children's Oncology Group Active, Not Recruiting 2026-08-19
NCT05457556 Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for… Children's Oncology Group Active, Not Recruiting 2026-07-30
NCT07735117 Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine… Ruijin Hospital Not Yet Recruiting 2026-07-29
NCT07722988 A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating… Kyntra Bio Not Yet Recruiting 2026-07-23
NCT05949684 ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants… Bristol-Myers Squibb Active, Not Recruiting 2026-06-30
NCT03173248 Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants… Institut de Recherches Internationales Servier Active, Not Recruiting 2026-06-29
NCT07653581 rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia Peking Union Medical College Hospital Not Yet Recruiting 2026-06-17
NCT06045689 A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants Bristol-Myers Squibb Active, Not Recruiting 2026-06-15
NCT04401748 Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change… AbbVie Active, Not Recruiting 2026-05-06
NCT04547049 A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From… First Affiliated Hospital of Zhejiang University Active, Not Recruiting 2026-04-09
NCT05316701 Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic… Orca Biosystems, Inc. Active, Not Recruiting 2026-03-04
NCT05181592 Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From… GWT-TUD GmbH Active, Not Recruiting 2025-09-30
NCT06927232 AZA+Lus VS AZA Monotherapy in HR-MDS Peking Union Medical College Hospital Not Yet Recruiting 2025-04-15
NCT05883956 A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and… Otsuka Australia Pharmaceutical Pty Ltd Active, Not Recruiting 2025-03-20
See all 561 active Myelodysplastic Syndromes (MDS) trials with filters →

Top sponsors by active trials in this area

M.D. Anderson Cancer Center (39) · National Cancer Institute (NCI) (28) · City of Hope Medical Center (22) · Fred Hutchinson Cancer Center (13) · Bristol-Myers Squibb (9) · Dana-Farber Cancer Institute (9) · Peking University People's Hospital (9) · Groupe Francophone des Myelodysplasies (8) · Masonic Cancer Center, University of Minnesota (7) · St. Jude Children's Research Hospital (7)

Get alerts when Myelodysplastic Syndromes (MDS) trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free